Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2013 Financial Results on Thursday, February 7th, at 4:30 P.M. EST

Mon Feb 4, 2013 12:01pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

TORONTO,  Feb. 4, 2013  /PRNewswire/ -  Transition Therapeutics Inc. 
("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a
 conference call on  Thursday, February 7th, 2013  at  4:30 P.M. EST  to
 discuss Second Quarter Fiscal 2013 financial results.   Dr.  Tony Cruz,
 Chairman and Chief Executive Officer of the Company, will host the
 call. Transition will announce its financial results for this period in
 a press release to be issued prior to the call.  In order to
 participate in the conference call, please call 1-800-773-0519 (North
 America), 1-212-231-2934 (International).  A replay of the conference
 call will be available on Transition's website 
for seven days following the call.

About Transition  

Transition is a biopharmaceutical company, developing novel therapeutics
 for disease indications with large markets. Transition's lead product
 is ELND005 for the treatment of Alzheimer's disease and bipolar
 disorder.  Transition also has an emerging pipeline of innovative
 preclinical and clinical drug candidates. The other drugs in the
 pipeline that the Company is developing are for anti-inflammatory and
 metabolic indications. Transition's shares are listed on the NASDAQ
 under the symbol "TTHI" and the Toronto Stock Exchange under the symbol
 "TTH". For additional information about the Company, please visit

Notice to Readers: Information contained in our press releases should be
 considered accurate only as of the date of the release and may be
 superseded by more recent information we have disclosed in later press
 releases, filings with the OSC, SEC or otherwise. Except for historical
 information, this press release may contain forward-looking statements,
 relating to expectations, plans or prospects for Transition, including
 conducting clinical trials and potential efficacy of its products.
 These statements are based upon the current expectations and beliefs of
 Transition's management and are subject to certain risks and
 uncertainties that could cause actual results to differ materially from
 those described in the forward-looking statements. These risks and
 uncertainties include factors beyond Transition's control and the risk
 factors and other cautionary statements discussed in Transition's
 quarterly and annual filings with the Canadian commissions.

SOURCE  Transition Therapeutics Inc.

For further information on Transition, visit

or contact:

Dr. Tony Cruz

Chief Executive Officer

Transition Therapeutics Inc.

Phone: 416-260-7770, x.223

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.